Muz Mansuri joined F-Prime in January 2020 as a Venture Partner and is based in the Cambridge office. Muz will be working with various F-Prime team members to evaluate therapeutic and digital investment and company creation opportunities. Muz has more than 35 years of experience in various R&D roles as a senior executive within the global biopharmaceutical industry.
Prior to joining F-Prime, Muz was a member of the Executive Committee at Sanofi, as Executive Vice President, Strategy, Business Development, and Licensing. Among other responsibilities, Muz headed the Strategy, Business Development, Alliance Management and the Venture Group for Sanofi. Before this, he was at Gilead Sciences as Senior Vice President, Research and Development Strategy and Business Development. In that capacity he led the R&D Strategy, Business Development, and M&A activities for the company. Muz has served as Chief Executive Officer of several biotech companies and as a General Partner at Flagship Ventures (now Flagship Pioneering). He began his career in the pharmaceutical industry as a bench medicinal chemist with Bristol Myers.
Muz received his B.Sc. and PhD in Chemistry from the University College London. He conducted postdoctoral research at UCLA and Columbia University.
Mike is the Head of Technology and Data Science at F-Prime, where he focuses on opportunities in healthcare technology and data science. Previously Mike worked at Beam Therapeutics, F-Prime, General Motors, and Applied Quantum Technologies.
Mike holds an M.B.A. from the University of Virginia’s Darden School of Business, an M.Eng. in Mechanical Engineering and B.S.E. in Mechanical and Electrical Engineering from Duke University.
Nikhil Ananth is a Principal at F-Prime and invests across multiple subsectors including therapeutics, medical technology, research tools, and life science software & services. Since joining F-Prime in 2019, Nikhil has supported investments in several companies including Adela, Countable Labs, Ensoma, Galatea Bio, Invetx (acquired by Dechra), Ivenix (acquired by Fresenius Kabi), Metsera (NASDAQ: MTSR, acquired by Pfizer), and Rallybio (NASDAQ: RLYB), among others. Nikhil also works closely with the Eight Roads Ventures team to manage F-Prime’s healthcare investments in India.
Prior to joining F-Prime, Nikhil was an Associate at Audax Group in Boston, where he focused on private equity investments in healthcare and software. Nikhil is a graduate of the University of Pennsylvania’s Vagelos Program in Life Sciences & Management, where he received a B.A. in Biology and a B.S. in Economics from the Wharton School.
Sam Bisbee is a Venture Partner at F-Prime with a background in technology, cybersecurity, and operations. He is also the Chief Security Officer at Threat Stack where he’s responsible for the company’s security and compliance programs, in addition to providing security services to Threat Stack’s Cloud SecOps Program customers.
Sam joined Threat Stack in 2014 to build and help bring the product to market. Previously Sam was a member of the Cloudant team (acquired by IBM).
Sandor is a Venture Partner at F-Prime, focusing on enterprise technology and cybersecurity. Previously he served as the CTO of LogMeIn where he drove the technology vision and development of the Identity and Remote Management portfolio (LastPass, LogMeIn Central, LogMeIn Pro, and GoToMyPC) and led the corporate IT and Security teams, navigating through many acquisitions and the merger with Citrix Online.
Sandor earned his master’s degree in Computer Science at the Budapest University of Technology and Economics and spent the early part of his career at Digital Equipment.
Connie is a Principal on the life sciences team at F-Prime based in San Francisco. She focuses primarily on biotechnology investments and also works closely with the Eight Roads Ventures China team to manage F-Prime’s existing and new investment efforts in China. Connie joined F-Prime in 2019, and has been involved in a number of company formation efforts including K36 Tx, Skyline, Pediatrix, and AlphaGen. Prior to joining F-Prime, Connie was a Consultant with IQVIA in New York, where she advised biopharmaceutical companies on commercial, development, and portfolio strategy topics.
Connie holds an M.B.A from Harvard Business School, M.S. from the Harvard Department of Stem Cell and Regenerative Biology, and a B.S.E. in Bioengineering from the University of Pennsylvania.
Martin is Principal based in the Cambridge office. Martin’s primary area of interest is in biotechnology investment and company creation efforts in a range of therapeutic areas including oncology, cardiovascular, renal and metabolic diseases, and rare disease. Martin joined F-Prime’s London office in 2019, where he has worked on several biotechnology company creation efforts and investments in Europe, including ARTBIO, CHARM Therapeutics and Tenpoint Therapeutics.
Prior to joining F-Prime, he was a Wellcome Trust Sir Henry Wellcome Postdoctoral Fellow at the MRC Laboratory of Molecular Biology in Cambridge, where he researched molecular mechanisms of DNA replication. Martin completed his PhD at the Cancer Research UK London Research Institute, prior to its incorporation into the Francis Crick Institute, investigating DNA repair by homologous recombination. His research has been published in several original articles in journals such as Cell, Nature and Molecular Cell. Martin also holds BA and MSci degrees in Biochemistry from the University of Cambridge.
Carlos Bustamante joined F-Prime in January 2019 as a Venture Partner based in the San Francisco office, and is focused on the application of data science and genomics technology to problems in medicine, agriculture, and biology. He is currently on leave from Stanford University where he is a Professor of Biomedical Data Science, Genetics, and (by courtesy) Biology, was founding Director of the Stanford Center for Computational, Evolutionary, and Human Genomics and is Inaugural Chair of the Department of Biomedical Data Science.
Carlos has a passion for building new academic units, non-profits, and companies to solve pressing scientific challenges. He is currently a Director at EdenRoc Sciences, LLC and Etalon DX, founder of Arc Bio, LLC and CDB Consulting LTD., and has served as an SAB member for more than a dozen companies.
Carlos received his PhD in Biology and MS in Statistics from Harvard University.
Rosy Howell joined the F-Prime team in March 2017. She is Executive Assistant to Alex Pasteur and Nihal Sinha. Previously, she worked at Henry Milner & Co. as Office Manager and Executive Assistant to Henry Milner. Rosy received her BA in Philosophy and English from the University of Southampton.
Josh is a cofounder of Stavvy, a Boston-based fintech company, where he leads product, engineering, people, and finance. A lifelong technologist, Josh has focused on entrepreneurship, financial services, cybersecurity, privacy, and anti-fraud technology. Josh has been responsible for building and leading teams — from niche startups to large federal agencies — tackling some of the world’s largest fraud, abuse, and security challenges. Before Stavvy, he served as the Chief Security Officer (CSO) at DigitalOcean where he oversaw the legal operations, trust & safety, security, and fraud & abuse teams. Josh also launched Rapid7’s security organization, operating as the CSO he functioned as one of the corporate spokespeople and a member of the product leadership team. In addition to his operational background, Josh continues to serve as a professional advisor at the Martin Trust Center for MIT Entrepreneurship.
Josh earned his Bachelor’s degree from the University of Maryland and his MBA from the Sloan School of Management at MIT.